icon-folder.gif   Conference Reports for NATAP  
 
  The Liver Meeting
San Francisco
November 2018
Back grey_arrow_rt.gif
 
 
 
Efficacy and Safety of Elbasvir/Grazoprevir for 8 or 12 Weeks
in Participants With Hepatitis C Virus Genotype 4 Infection

 
 
  Reported by Jules Levin
AASLD 2018 Nov 9-12 Boston
 
Tarik Asselah1; Stanislas Pol2; Christophe Hezode3; Veronique Loustaud-Ratti4; Vincent Leroy5; Si Nafa Si Ahmed6; Violaine Ozenne7; Jean-Pierre Bronowicki8; Dominique Larrey9; Albert Tran10; Laurent Alric11; Eric Nguyen-Khac12; Michael N. Robertson13; George J. Hanna13; Deborah Brown13; Ernest Asante-Appiah13; Steve Ludmerer13; Feng-Hsiu Su13; Peggy Hwang13; Stephanie Klopfer13; Jessie Durrand Hall13; Amir Guidoum13; Karin Hagen13; Barbara A. Haber13; Rohit Talwani13; Lawrence Serfaty14 1Hopital Beaujon, Clichy, France; 2APHP/Universite Paris Descartes, Paris, France; 3Henri Mondor Hospital, Creteil, France; 4CHU Limoges, Limoges, France; 5CHU Grenoble Alpes, Grenoble, France; 6Pole de Recherche Clinique, Hepato Gastroenterologie, Hopital Saint Joseph, Marseille, France; 7Hopital Saint Antoine, Paris, France; 8CHU Nancy, Nancy, France; 9Hopital Saint Eloi, Montpellier School of Medicine, Montpellier, France; 10Hopital l'Archet 2, Nice, France; 11CHU de Toulouse, Toulouse, France; 12CHU Amiens, Amiens, France; 13Merck & Co., Inc., Kenilworth, NJ, USA; 14Hopital de Hautepierre, Universitaires de Strasbourg, Strasbourg, France

1114181

1114182

1114183

1114184

1114185

1114186